SEC Filing Document

Company: DUKE Robotics Corp.
Ticker: DUKR
CIK: 1638911
Filing Type: DRS
Document Type: DRS
Date Filed: 2025-12-22
Accession Number: 0001213900-25-124553
Exchange: OTC
SIC Code: 3721
SIC Description: Aircraft
URL: https://www.sec.gov/Archives/edgar/data/1638911/000121390025124553/filename1.htm

Chunk 14 of 51
Word Count: 1469
Character Count: 9485

Document Content:

services and continue our current operations. If our common stock price declines, we can offer no assurance that we will be able to raise additional capital or generate funds from operations sufficient to meet our obligations. If we are unable to raise sufficient capital in the future, we may not be able to have the resources to continue our normal operations. The requirements of being a public company may strain our resources and distract management. As a public company, we are subject to the reporting requirements of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) and the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”). These requirements are extensive. The Exchange Act requires that we file annual, quarterly and current reports with respect to our business and financial condition. The Sarbanes-Oxley Act requires that we maintain effective disclosure controls and procedures and internal controls over financial reporting.

We may incur significant costs
associated with our public company reporting requirements and costs associated with applicable corporate governance requirements. We expect
all of these applicable rules and regulations to significantly increase our legal and financial compliance costs and to make some activities
more time consuming and costly. This may divert management’s attention from other business concerns, which could have a material
adverse effect on our business, financial condition and results of operations. We also expect that these applicable rules and regulations
may make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to accept
reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be
more difficult for us to attract and retain qualified individuals to serve on our board of directors or as executive officers. We are
currently evaluating and monitoring developments with respect to these rules, and we cannot predict or estimate the amount of additional
costs we may incur or the timing of such costs.

Future changes in financial accounting standards
or practices may cause adverse unexpected financial reporting fluctuations and affect reported results of operations.

A change in accounting standards
or practices can have a significant effect on our reported results and may even affect our reporting of transactions completed before
the change is effective. New accounting pronouncements and varying interpretations of accounting pronouncements have occurred and may
occur in the future. Changes to existing rules or the questioning of current practices may adversely affect our reported financial results
or the way we conduct business.

USE OF PROCEEDS

Assuming no exercise of the underwriters’ over-allotment option
or of the warrants issued in this offering, including the Representative’s Warrants, and the: (i) uplist to Nasdaq of our common
stock; (ii) a [   ] reverse common stock split effected by the Board and (iii) [___] Units sold in the offering at a public
offering price per share of $[___], we estimate that the net proceeds from this offering will be approximately $[   ] after
deducting estimated underwriting discounts and estimated offering expenses payable by us. Assuming the same, if the Representative’s
over-allotment option is exercised in full, we estimate that our net proceeds will be approximately $[   ]. We intend to
use the net proceeds from this offering, and any proceeds from the exercise of warrants included in the Units and the Representative’s
Warrants, for research and development, sales force expansion, marketing, business
development and potential acquisitions and for general working capital.

With Over-Allotment Without Over-Allotment

Uses:

Research and Development $

Sales Force Expansion, Marketing, Business Development and Potential Acquisitions $

Working Capital

Total Uses $

This is an estimated use of proceeds; the actual allocation of proceeds realized from this offering will depend
upon our operating revenues and cash position and our working capital requirements and may change.

Therefore, as of the date of this prospectus, we cannot specify with certainty all of the particular uses for
the net proceeds to be received upon the completion of this offering. Accordingly, we will have discretion in the application of the net
proceeds, and investors will be relying on our judgment regarding the application of the proceeds of this offering.

Pending our use of the net
proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including short-term,
investment-grade, interest-bearing instruments and U.S. government securities. We anticipate that the proceeds from this offering will
enable us to become cash flow from operations positive.

A [50]% increase (decrease)
in the public offering price of $[_____] per Unit would increase (decrease) the expected net proceeds of the offering to us by approximately
$[___] million, assuming that the number of shares of common stock sold by us remains the same. We may also increase or decrease the number
of Units we are offering.

Management believes that the
proceeds from this offering will be sufficient to satisfy the Company’s cash needs for the next [   ] months.

CAPITALIZATION

The following table sets forth
our capitalization as of September 30, 2025:

●	on an actual basis; and

●	on an as adjusted basis to reflect the issuance and sale of the Units in this offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by us and the receipt by us of the proceeds of such sale.

You should consider this table
in conjunction with “Use of Proceeds” above as well as our “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” and our financial statements and the notes to those financial statements included elsewhere
in this prospectus.

As of September 30,

Unaudited, Actual
(1) Unaudited, As Adjusted

Cash and cash equivalents $	361,000

Total Current Liabilities 362,000

Total Long-Term Liabilities 404,000

Stockholders’ Equity:

Common stock of US$ 0.0001 par value each: 100,000,000 shares authorized as of September 30, 2025 and December 31, 2024; issued and outstanding 54,218,813 shares as of September 30, 2025 and December 31, 2024. 5,000

Additional paid-in capital 12,158,000

Foreign currency translation adjustments (1,000	)

Accumulated deficit (11,940,000	)

Total Stockholders’ Equity $	222,000

(1)	On an actual basis as of September

(2)	On an as adjusted basis to
give effect to our receipt of estimated net proceeds from the sale of the Units that we are offering at a public offering price of $[_____]
per Unit after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Assumes
no exercise of the underwriters’ over-allotment option and no exercise of any of the warrants included in the Units or Representative’s
Warrants issued pursuant to this offering.

A [50]% increase (decrease)
in the public offering price of $[____] per Unit would increase (decrease) cash and cash equivalents, working capital, total assets, and
total stockholders’ (deficit) equity by $[_____] million, assuming that the number of Units offered by us, as set forth on the cover
page of this prospectus, remains the same, after deducting the estimated underwriting discounts and commissions, and assuming no exercise
of the underwriters’ over-allotment option and no exercise of any of the warrants included in the Units or Representative’s
Warrants issued pursuant to this offering.

The above discussion and table
are based on 54,218,813 shares of common stock outstanding as of September 30, 2025, and actual numbers do not give effect to our planned
reverse stock split. The discussion and table do not include, as of that date:

●	15,500,000 shares, [_______] shares as adjusted for the reverse stock split at [   ] ratio issuable upon exercise of warrants at a weighted average exercise price of $0.65 per share or $[____] per share as adjusted;

●	4,496,812 shares, [_______] shares as adjusted, of our common stock issuable upon exercise of outstanding options at a weighted average exercise price of $0.54 per share or $[____] per share as adjusted;

●	4,503,188 shares, [_______] shares as adjusted, of our common stock that are reserved for equity awards that may be granted under our existing equity incentive plans; and

●	[____] shares of common stock issuable upon the exercise of the Representative’s Warrants to be issued in this offering.

DETERMINATION OF OFFERING PRICE

The offering price of the
Units has been negotiated between us and the Representative. Among the factors considered in determining the public offering price
of the Units, including the exercise price of the warrants were:

●	our history and our prospects;

●	the industry in which we operate;

●	our past and present operating results;

●	the anticipated market price of our common stock following this offering, the expected volatility of our common stock, the terms of the warrants (including their duration and exercise mechanics), and the likelihood that the warrants would be exercised;

●	the previous experience of our executive officers; and

●	the general condition of the securities markets at the time of this offering.